Crystal Jones, NP
Adult Health · North Wilkesboro, NCNPI 1275914285
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 353 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$653
- GSK$604
- Amgen$414
- Novo Nordisk$313
- Johnson & Johnson$267
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,035100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 56 | $1,064 |
| AbbVie | 40 | $653 |
| GSK | 33 | $604 |
| Amgen | 35 | $414 |
| Novo Nordisk | 21 | $313 |
| Johnson & Johnson | 17 | $267 |
| Axsome Therapeutics, Inc. | 12 | $264 |
| Lilly USA, LLC | 12 | $245 |
| Otsuka America Pharmaceutical, Inc. | 14 | $235 |
| Pfizer | 11 | $196 |
| Boehringer Ingelheim | 13 | $194 |
| Bayer | 10 | $160 |
| Mylan Specialty L.p. | 9 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $124 |
| Xeris Pharmaceuticals, Inc. | 6 | $115 |
| Eisai Inc. | 4 | $110 |
| Idorsia Pharmaceuticals US Inc | 6 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $94 |
| Ardelyx, Inc. | 4 | $77 |
| Paratek Pharmaceuticals, Inc. | 5 | $77 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $74 |
| Novartis | 3 | $64 |
| Exact Sciences | 4 | $64 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Esperion Therapeutics, Inc. | 2 | $44 |
| Viatris Specialty LLC | 2 | $43 |
| Lundbeck LLC | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Abbott | 2 | $30 |
| Dexcom, Inc. | 1 | $29 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $12 |
How this compares
$6,035 in reported general payments places this provider in the 90th percentile of 614 adult health providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 202 | $195,002 |
| OzempicSemaglutide | 155 | $176,733 |
| FarxigaDapagliflozin Propanediol | 104 | $122,093 |
| LinzessLinaclotide | 86 | $88,780 |
| JardianceEmpagliflozin | 71 | $73,888 |
| MounjaroTirzepatide | 58 | $73,781 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $54,077 |
| TrulicityDulaglutide | 46 | $46,238 |
| XareltoRivaroxaban | 47 | $44,996 |
| JanuviaSitagliptin Phosphate | 30 | $35,525 |
| ViberziEluxadoline | 14 | $24,100 |
| RybelsusSemaglutide | 18 | $22,614 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $22,289 |
| MyrbetriqMirabegron | 25 | $20,885 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $19,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $196 | $202,119218 claims |
| Novo NordiskOzempic, Rybelsus | $313 | $199,347173 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,064 | $161,700209 claims |
| Lilly USA, LLCMounjaro, Trulicity | $245 | $120,019104 claims |
| AbbVieLinzess, Viberzi | $653 | $112,880100 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $194 | $93,208104 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $604 | $74,717107 claims |
| Johnson & JohnsonXarelto | $267 | $44,99647 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $20,88525 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $94 | $17,07319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 adult health providers in North Carolina.
Other adult health in North Wilkesboro
- Robert DodgeRaleigh$311K
- Kimberly CampDurham$147K
- Henry VanpalaRaleigh$110K
- Jolene SpencerWashington$83K
- Felicia RichardsonGreenville$64K
- Anna BooneReidsville$51K
- Chaely MedleyChapel Hill$47K
- Ann ShumDurham$35K
- Amy HopkinsGreenville$31K
- Stephanie YatesDurham$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.